Please login to the form below

Not currently logged in
Email:
Password:

China recalls GSK antibiotic

Chinese authorities have recalled GlaxoSmithKline's antibiotic Augmentin after traces of a compound used to make plastics more flexible were found in the treatment's syrup form

Chinese authorities have recalled GlaxoSmithKline's (GSK) antibiotic Augmentin (amoxicillin and clavulanate potassium) after traces of a compound used to make plastics more flexible were found in the treatment's syrup form.

Test results have shown the plasticiser diisodecyl phthalate (DIDP) is present in the antibiotic, according to China's State Food and Drug Administration. DIDP is banned in the production of medicines.

GSK has been ordered to immediately suspend sales of the product, which is regularly used to treat infections in children.

As reported in the UK's Daily Telegraph, a GSK spokesperson said: "GSK is currently in discussion with a number of regulatory agencies in the Asia Pacific region, some of whom have also conducted tests."

"The amount of phthalates identified as present in Augmentin syrup samples tested is very low; some tests have found none and the highest level reported by the authorities is 88 parts per million. Even this highest result is significantly lower than the levels that the US and European authorities deem as presenting no risk to humans."

Taiwan and Hong Kong had previously demanded GSK recall Augmentin after it was found to contain DIPD.

21st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics